the international, multicenter, double-blind trial (SAILING), 719 HIV-1- infected, antiretroviral
treatment-experienced adults were randomized and received either TIVICAY 50 mg once daily
or raltegravir 400 mg twice daily with investigator selected background regimen consisting of up
to 2 agents, including at least 1 fully active agent